Insider Selling: Versartis Inc (VSAR) Insider Sells 14,446 Shares of Stock

Versartis Inc (NASDAQ:VSAR) insider Jay Shepard sold 14,446 shares of the firm’s stock in a transaction on Thursday, February 8th. The stock was sold at an average price of $1.80, for a total value of $26,002.80. Following the sale, the insider now directly owns 602,298 shares in the company, valued at approximately $1,084,136.40. The sale was disclosed in a document filed with the SEC, which is available at the SEC website.

Versartis Inc (NASDAQ VSAR) traded up $0.10 on Monday, hitting $1.80. The company’s stock had a trading volume of 333,801 shares, compared to its average volume of 632,748. Versartis Inc has a 1 year low of $1.60 and a 1 year high of $24.00. The firm has a market cap of $60.88, a P/E ratio of -0.46 and a beta of 2.11. The company has a debt-to-equity ratio of 0.11, a current ratio of 1.52 and a quick ratio of 1.52.

Several institutional investors and hedge funds have recently added to or reduced their stakes in the business. Parametric Portfolio Associates LLC raised its stake in shares of Versartis by 1.7% in the 2nd quarter. Parametric Portfolio Associates LLC now owns 32,597 shares of the biopharmaceutical company’s stock valued at $569,000 after purchasing an additional 535 shares during the period. Schwab Charles Investment Management Inc. raised its stake in shares of Versartis by 0.6% in the 2nd quarter. Schwab Charles Investment Management Inc. now owns 109,409 shares of the biopharmaceutical company’s stock valued at $1,910,000 after purchasing an additional 627 shares during the period. The Manufacturers Life Insurance Company raised its stake in shares of Versartis by 4.8% in the 2nd quarter. The Manufacturers Life Insurance Company now owns 26,326 shares of the biopharmaceutical company’s stock valued at $459,000 after purchasing an additional 1,204 shares during the period. Goldman Sachs Group Inc. raised its stake in shares of Versartis by 2.2% in the 2nd quarter. Goldman Sachs Group Inc. now owns 103,044 shares of the biopharmaceutical company’s stock valued at $1,798,000 after purchasing an additional 2,260 shares during the period. Finally, Cornerstone Capital Management Holdings LLC. raised its stake in shares of Versartis by 13.6% in the 2nd quarter. Cornerstone Capital Management Holdings LLC. now owns 24,714 shares of the biopharmaceutical company’s stock valued at $431,000 after purchasing an additional 2,967 shares during the period. 48.73% of the stock is currently owned by hedge funds and other institutional investors.

Several analysts recently commented on VSAR shares. Zacks Investment Research downgraded Versartis from a “hold” rating to a “sell” rating in a research note on Sunday, January 21st. Cantor Fitzgerald set a $14.00 price objective on Versartis and gave the stock a “buy” rating in a research note on Friday, October 27th. Two research analysts have rated the stock with a sell rating, eight have assigned a hold rating and two have given a buy rating to the company’s stock. The stock currently has an average rating of “Hold” and an average price target of $5.63.

WARNING: “Insider Selling: Versartis Inc (VSAR) Insider Sells 14,446 Shares of Stock” was posted by American Banking News and is the property of of American Banking News. If you are accessing this report on another publication, it was illegally stolen and republished in violation of United States & international copyright law. The correct version of this report can be accessed at https://www.americanbankingnews.com/2018/02/12/insider-selling-versartis-inc-vsar-insider-sells-14446-shares-of-stock.html.

About Versartis

Versartis, Inc is an endocrine-focused biopharmaceutical company. The Company is engaged in developing a long-acting form of recombinant human growth hormone, somavaratan (VRS-317), for growth hormone deficiency (GHD), an orphan disease. The Company’s first indication for somavaratan is pediatric GHD.

Insider Buying and Selling by Quarter for Versartis (NASDAQ:VSAR)

Receive News & Ratings for Versartis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Versartis and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply